摘要
目的:探讨比较不同剂量尿激酶对心肌梗死患者的综合临床疗效。方法:将2005年1月～2011年3月于本院进行治疗的90例急性心肌梗死患者随机分为A组(50万U尿激酶组)、B组(100万U尿激酶组)和C组(150万U尿激酶组),各30例,将三组患者的治疗总有效率、不良反应发生率及治疗前后的血清cTnI、CK-MB、AST、LDH及CRP水平进行统计及比较。结果:B组(96.67%)和C组(96.67%)的治疗总有效率高于A组(86.67%);血清cTnI、CK-MB、AST、LDH及CRP水平,B组[(0.70±0.18)μg/L,(7.70±2.86)U/L,(27.02±6.54)U/L,(175.96±19.12)U/L,(6.71±2.40)mg/L]和C组[(0.56±0.19)μg/L,(7.31±2.98)U/L,(25.10±6.89)U/L,(172.14±18.65)U/L,(6.52±2.37)mg/L]低于A组[(6.85±2.34)μg/L,(13.25±5.67)U/L,(54.63±8.15)U/L,(236.50±33.18)U/L,(10.39±3.65)mg/L];B组不良反应发生率(16.67%)低于C组(26.67%)。各指标差异均有统计学意义(P<0.05)。结论:100万U的尿激酶在心肌梗死中的治疗效果较好,安全性也较高,综合优势明显。
Objective： To study and compare the comprehensive therapeutic effect of different doses of Urokinase in patients with myocardial infarction.Methods： 90 patients with myocardial infarction in our hospital from January 2005 to March 2011 were selected as research object,and they were randomly divided into group A（0.5 million units Urokinase group）,group B（1 million units Urokinase group） and group C（1.5 million units Urokinase group）,30 cases in each group.The total effective rates,incidence of adverse reactions and serum cTnI,CK-MB,AST,LDH,CRP before and after the treatment of three groups were analyzed and compared.Results： The total effective rates of group B（96.67%） and group C（96.67%） were higher than that of group A（86.67%）;serum cTnI,CK-MB,AST,LDH,CRP of group B [（0.70±0.18）μg/L,（7.70±2.86）U/L,（27.02±6.54）U/L,（175.96±19.12）U/L,（6.71±2.40）mg/L] and group C[（0.56±0.19）μg/L,（7.31±2.98）U/L,（25.10±6.89）U/L,（172.14±18.65）U/L,（6.52±2.37）mg/L] were lower than those of group A[（6.85±2.34）μg/L,（13.25±5.67）U/L,（54.63±8.15）U/L,（236.50±33.18）U/L,（10.39±3.65）mg/L];incidence of adverse reactions of group B（16.67%） were lower than that of group C（26.67%）,all the differences were significant（P〈0.05）.Conclusion： The clinical effect of the dose of 1 million units Urokinase in myocardial infarction is better,the safety is higher,and its comprehensive advantage is obvious.
出处
《中国医药导报》
CAS
2011年第28期67-68,73,共3页
China Medical Herald
关键词
不同剂量
尿激酶
心肌梗死
临床疗效
Different doses
Urokinase
Myocardial infarction
Clinical effect
